Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Edrecolomab, an antibody targeting EPCAM.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Arcitumomab, an antibody targeting CEA.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Abciximab, an antibody targeting ITGA2B.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Basiliximab, an antibody targeting IL2RA.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Satumomab, an antibody targeting TAG72.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ibritumomab, an antibody targeting CD20.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Efalizumab, an antibody targeting ITGAL.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ibalizumab, an antibody targeting CD4.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Moxetumomab, an antibody targeting SIGLEC2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ozoralizumab, an antibody targeting TNF × ALB.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Idarucizumab, an antibody targeting Dabigatran.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Enfortumab, an antibody targeting PVRL4.